Axe Compute Inc (NASDAQ: AGPU) is a company in the process of pivoting from oncology drug discovery services to AI compute infrastructure, with a digital asset treasury strategy centered on ATH, the native utility token of the Aethir ecosystem. The company raised approximately $343.5 million through two PIPE transactions that closed October 7, 2025, funding the acquisition of ATH tokens as a treasury asset. The legacy business, operated under a Drug Discovery Services segment, includes the PEDAL platform, an AI-driven drug-response prediction tool combining a biobank of tumor samples with multi-omic data, and 3D tumor modeling services sold to pharmaceutical, diagnostic, and biotech companies. As of February 2026, the company engaged Cardiff Advisory LLC to explore strategic alternatives for its legacy biobank and drug discovery operations, including a potential sale, partnership, or licensing arrangement, signaling that the legacy segment is being treated as non-core. Christopher Miglino was appointed Chief Executive Officer effective February 9, 2026, following the termination of Raymond F. Vennare.

Revenue model

The legacy Drug Discovery Services segment generated transactional and contract-based revenue from pharmaceutical, diagnostic, and biotech partners for drug-response prediction services, biomarker discovery, drug screening, and 3D tumor modeling. The current strategic focus is a digital asset treasury model built around ATH token holdings accumulated through the October 2025 PIPE transactions. Revenue model details for the compute infrastructure strategy are not specified in the filing excerpts.

Products and services

Legacy segment: PEDAL (Patient-centric Drug Discovery using Active Learning), an AI-driven drug-response prediction platform combining a privately held commercial biobank of tumor samples, active machine learning, CLIA-certified lab testing, and multi-omic historical tumor data. CORE, an active machine learning program embedded in PEDAL. 3D tumor-specific in vitro models for oncology drug discovery. Genomic Profiling services offering clinically relevant protein expression and genomic mutation tests organized by cancer pathway and tumor type. New strategy: ATH digital asset treasury holdings, with AI compute infrastructure as the stated strategic direction.

Customers and end markets

Legacy customers include pharmaceutical, diagnostic, and biotech companies seeking multi-omic insights into cancer drug response, biomarker development, drug screening, and clinical trial optimization. The filing does not disclose specific customer names, customer concentration data, or revenue by customer for any fiscal period.

Value-chain role

In the legacy business, the company operates as a contract research and drug discovery services provider sitting between early-stage oncology drug candidates and clinical trials, supplying predictive drug-response data to biopharma partners. In the new strategy, the company positions itself as a GPU compute infrastructure and AI cloud services operator, competing with specialized GPU cloud platforms and distributed GPU infrastructure providers, though operational details of that business are not specified in the filing excerpts.

Geographic exposure

The filing does not disclose geographic revenue breakdown or specific operating geographies beyond the U.S. incorporation in Delaware and the auditor's location in Pittsburgh, PA.

Competitors

Specialized GPU cloud platforms, Dedicated AI data center infrastructure operators, Distributed GPU infrastructure providers, Major public hyperscale cloud providers

Source: SEC 10-K, filed 2026-03-31

Industry: Finance Services Peers: Xtant Medical Holdings Inc SURGALIGN HOLDINGS, INC. Innovative Eyewear Inc United Health Products Inc Rockwell Medical Inc Retractable Technologies Inc VolitionRX Ltd PROJECT SAGE OLDCO, INC.